Novel fidaxomicin antibiotics through site-selective catalysis

Fidaxomicin (FDX) is a marketed antibiotic for the treatment of Clostridioides difficile infections (CDI). Fidaxomicin displays antibacterial properties against many Gram-positive bacteria, yet the application of this antibiotic is currently limited to treatment of CDI. Semisynthetic modifications p...

Descripción completa

Detalles Bibliográficos
Autores principales: Dailler, David, Dorst, Andrea, Schäfle, Daniel, Sander, Peter, Gademann, Karl
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9814943/
https://www.ncbi.nlm.nih.gov/pubmed/36697765
http://dx.doi.org/10.1038/s42004-021-00501-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9814943/
https://www.ncbi.nlm.nih.gov/pubmed/36697765
http://dx.doi.org/10.1038/s42004-021-00501-6

Ejemplares similares